SLAS Announces the Cohort for Innovation AveNEW at SLAS Europe 2026

Why It Matters

The program provides critical market access and validation for life‑science startups, accelerating adoption of innovative automation tools across the global R&D ecosystem.

Key Takeaways

• 12 startups from 7 countries selected for SLAS Europe 2026
• SLAS covers exhibition fees, travel and lodging for one representative
• Ignite Award winner receives €5,000 (~$5,450) cash prize
• Startups may publish research in SLAS Discovery or Technology journals
• Program links startups with decision‑makers from over 40 countries

Pulse Analysis

The Society of Laboratory Automation and Screening (SLAS) has long positioned itself as a catalyst for early‑stage innovation in life‑science research. Its Innovation Ave NEW program, launched in 2018, offers a curated showcase for emerging companies that are redefining laboratory automation, high‑throughput screening, and digital biology. By gathering startups under one banner at the SLAS Europe conference in Vienna, the society creates a high‑visibility arena where cutting‑edge technologies can be evaluated side‑by‑side with established industry players. This model not only accelerates product validation but also fuels cross‑border collaborations essential for the rapidly globalizing biotech ecosystem.

The 2026 cohort comprises twelve firms spanning Germany, the United States, Australia, the United Kingdom, France, the Netherlands, and Belgium, reflecting the program’s geographic breadth. SLAS shoulders exhibition fees and provides travel and lodging for a company representative, removing a common financial barrier for fledgling ventures. In addition, participants gain access to business mentorship, the chance to submit manuscripts to the open‑access SLAS Discovery and Technology journals, and eligibility for the €5,000 (approximately $5,450) Ignite Award. Such resources compress the time‑to‑market for novel platforms ranging from robotic liquid handlers to AI‑driven assay analytics.

The exposure to purchasing influencers from more than forty countries can translate into rapid customer acquisition and strategic partnership opportunities. For investors, the Innovation Ave NEW stage serves as a de‑risking filter, highlighting startups that have cleared technical merit and commercial feasibility thresholds. As laboratory automation becomes a cornerstone of drug discovery and personalized medicine, the program’s emphasis on scalable, data‑rich solutions positions its alumni to capture a growing share of R&D spend. Consequently, the cohort’s success will likely ripple through the broader life‑science supply chain, shaping next‑generation research workflows.